Tempest Therapeutics Inc (TPST) Stock Price, Quote & News

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 798 8589

Website: www.tempesttx.com

Address:

2000 Sierra Point Parkway, Suite 400, Brisbane, United States

lgb2 Sep. 13 at 1:14 PM

$TPST $2.38

0 · Reply

lgb2 Sep. 13 at 1:13 PM

$TPST sad to say

0 · Reply

et1000 Sep. 11 at 11:11 PM

Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $TPET $TPST $BURU $FFAI cn

0 · Reply

TwongStocks Sep. 11 at 6:33 PM

$TPST Waiting for the registration statement on today's offering. Looking for the following info: 1) Updated outstanding shares. Will we see confirmation that they already started selling shares to Lincoln Park prior to today's offering? 2) Since this is a private placement, they have to register the shares for resale. The registration statement will disclose the selling stockholders. This will allow us to confirm who took part in the offering. We should be able to see if Factor, Angel, or Lotus also participated in the offering.

0 · Reply

HectorNumba9 Sep. 11 at 6:30 PM

$TPST U was scared huh. Easy scoop. Mad didnt catch the 50cs. Keep complaining

0 · Reply

Michl2000 Sep. 11 at 5:15 PM

$TPST Halted ?

0 · Reply

PennySearch Sep. 11 at 3:33 PM

📈 Top Penny Stock Movers by Relative Volume $TNON — 7.04x RVOL Move: +67% Volume: 68.0M (9.7M average) Market Cap: $4.3M Day Range: 7.04 – 10.39 52-Week Range: 2.40 – 50.40 $CRMT — 4.53x RVOL Move: +26% Volume: 1.7M (385.0K average) Market Cap: $16.9M Day Range: 1.63 – 2.14 52-Week Range: 1.37 – 35.38 $TPST — 2.45x RVOL Move: +6% Volume: 668.8K (273.4K average) Market Cap: $13.5M Day Range: 0.76 – 0.89 52-Week Range: 0.76 – 12.23 Momentum and unusual volume are driving attention. Which one are you watching? 👀 Not financial advice.

0 · Reply

jyc990 Sep. 11 at 2:22 PM

$TPST now it can run up for the presentation next week

0 · Reply

RunItUp1000 Sep. 11 at 1:20 PM

$TPST short entry at open. Expect a pullback to .50

4 · Reply

Xamayca Sep. 11 at 1:16 PM

$TPST Added @.76

0 · Reply

Tempest Therapeutics announces $7.5M private placement

Sep 11, 2026, 8:00 AM EDT - 2 days ago

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

Sep 8, 2026, 8:30 AM EDT - 5 days ago

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

2026-08-21T20:50:21.000Z - 22 days ago

Tempest Therapeutics files to sell 8.91M shares of common stock for holders

Aug 21, 2026, 8:00 AM EDT - 23 days ago

Tempest Therapeutics Registration statement: Registration filing

Aug 18, 2026, 8:00 AM EDT - 26 days ago

Tempest Therapeutics Proxy statement: Proxy filing

Aug 13, 2026, 4:25 PM EDT - 4 weeks ago

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Tempest Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Tempest Therapeutics Quarterly report: Q2 2026

Jul 28, 2026, 8:00 AM EDT - 6 weeks ago

Tempest Therapeutics Proxy statement: Proxy filing

Jul 21, 2026, 7:00 AM EDT - 7 weeks ago

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Jul 17, 2026, 8:00 AM EDT - 1 month ago

Tempest Therapeutics Proxy statement: Proxy filing

Jul 15, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Slides: Corporate presentation

Jul 15, 2026, 7:00 AM EDT - 2 months ago

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Jul 7, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Proxy statement: Proxy filing

2026-06-26T20:10:33.000Z - 2 months ago

Tempest Therapeutics registers to sell 2.43M shares of common stock for holders

Jun 26, 2026, 8:00 AM EDT - 2 months ago

Tempest Therapeutics Registration statement: Registration filing

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Proxy statement: Proxy filing

Jun 4, 2026, 4:37 PM EDT - 3 months ago

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

May 29, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026, 8:00 AM EDT - 3 months ago

Tempest Therapeutics Proxy statement: Proxy filing

May 14, 2026, 4:15 PM EDT - 4 months ago

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 4:00 PM EDT - 4 months ago

Tempest Therapeutics Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 4 months ago

Tempest Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 4 months ago

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026, 7:00 AM EDT - 4 months ago

Tempest Therapeutics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

2026-04-22T12:30:21.000Z - 4 months ago

Tempest Therapeutics provides update on development of TPST-2003

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Apr 14, 2026, 8:00 AM EDT - 5 months ago

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Registration statement: Registration filing

2026-04-02T10:11:28.000Z - 5 months ago

Tempest Therapeutics files to sell 2.78M shares of common stock for holders

2026-03-30T22:05:33.000Z - 5 months ago

Tempest Therapeutics files to sell 8.27M shares of common stock for holders

Mar 30, 2026, 9:00 AM EDT - 5 months ago

Tempest Reports Year End 2025 Financial Results and Provides Business Update

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Tempest Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:30 AM EDT - 5 months ago

Tempest Therapeutics Earnings release: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Registration statement: Registration filing

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Tempest Therapeutics Announces Up To $6 Million Private Placement

2026-03-11T12:06:24.000Z - 6 months ago

Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study

Mar 11, 2026, 8:00 AM EDT - 6 months ago

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

2026-02-25T13:24:11.000Z - 6 months ago

Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003

Feb 25, 2026, 7:59 AM EST - 6 months ago

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

Feb 11, 2026, 6:59 AM EST - 7 months ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 7 months ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

2026-01-22T11:12:02.000Z - 7 months ago

Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Jan 20, 2026, 5:20 PM EST - 7 months ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Dec 31, 2025, 7:00 AM EST - 8 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

2025-12-09T21:55:14.000Z - 9 months ago

Tempest Therapeutics files to sell 1.17M shares of common stock for holders

Dec 9, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Registration statement: Registration Filing

Dec 2, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 26, 2025, 4:05 PM EST - 9 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

2025-11-25T13:05:18.000Z - 9 months ago

Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering

Nov 25, 2025, 8:00 AM EST - 9 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

2025-11-19T14:11:00.000Z - 9 months ago

Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience

Nov 19, 2025, 9:00 AM EST - 9 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Nov 19, 2025, 7:00 AM EST - 9 months ago

Tempest Therapeutics Proxy statement: Proxy Filing

Nov 5, 2025, 9:00 AM EST - 10 months ago

Tempest Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 10 months ago

Tempest Therapeutics Earnings release: Q3 2025

2025-11-05T13:36:56.000Z - 10 months ago

Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year

Nov 5, 2025, 8:30 AM EST - 10 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-08-11T20:55:19.000Z - 1 year ago

Tempest Therapeutics reports Q2 EPS ($2.07), consensus ($2.65)

Aug 11, 2025, 4:12 PM EDT - 1 year ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q2 2025

2025-06-30T14:37:56.000Z - 1 year ago

Tempest Therapeutics receives NMPA clearance to proceed with amezalpat trial

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

2025-06-11T12:20:36.000Z - 1 year ago

Tempest prices 739,000 shares at $6.25 in registered direct offering

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

May 13, 2025, 4:28 PM EDT - 1 year ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q1 2025

Apr 28, 2025, 4:05 PM EDT - 1 year ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 9, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Tempest Therapeutics Slides: Corporate Presentation

Mar 27, 2025, 4:10 PM EDT - 1 year ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:00 PM EDT - 1 year ago

Tempest Therapeutics Earnings release: Q4 2024

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 24, 2025, 7:00 AM EST - 1 year ago

Tempest Therapeutics Registration statement: Registration Filing

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Dec 3, 2024, 9:00 AM EST - 1 year ago

Tempest Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Tempest Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Tempest Therapeutics Proxy statement: Proxy Filing

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Tempest Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:00 AM EDT - 2 years ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 8, 2024, 4:56 PM EDT - 2 years ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q2 2024

Jul 19, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Registration statement: Registration Filing

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Transcript: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Slides: Study Update

Jun 20, 2024, 8:30 AM EDT - 2 years ago

Tempest Therapeutics Press release: Study Update

Jun 18, 2024, 6:22 PM EDT - 2 years ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 5, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: Jefferies Global Healthcare Conference

May 29, 2024, 2:00 PM EDT - 2 years ago

Tempest Therapeutics Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 9, 2024, 4:29 PM EDT - 2 years ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Tempest Therapeutics Earnings release: Q1 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Tempest Therapeutics Proxy statement: Proxy Filing

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

lgb2 Sep. 13 at 1:14 PM

$TPST $2.38

0 · Reply

lgb2 Sep. 13 at 1:13 PM

$TPST sad to say

0 · Reply

et1000 Sep. 11 at 11:11 PM

0 · Reply

TwongStocks Sep. 11 at 6:33 PM

0 · Reply

HectorNumba9 Sep. 11 at 6:30 PM

$TPST U was scared huh. Easy scoop. Mad didnt catch the 50cs. Keep complaining

0 · Reply

Michl2000 Sep. 11 at 5:15 PM

$TPST Halted ?

0 · Reply

PennySearch Sep. 11 at 3:33 PM

0 · Reply

jyc990 Sep. 11 at 2:22 PM

$TPST now it can run up for the presentation next week

0 · Reply

RunItUp1000 Sep. 11 at 1:20 PM

$TPST short entry at open. Expect a pullback to .50

4 · Reply

Xamayca Sep. 11 at 1:16 PM

$TPST Added @.76

0 · Reply

Michl2000 Sep. 11 at 12:51 PM

$TPST quite good guess 😁

0 · Reply

Michl2000 Sep. 11 at 12:49 PM

$TPST always the same pattern. Small biotechs doing the dirt-work development for Big Pharma and small biotech investors pay the bill i.e. most of development costs for Big Bharma.

0 · Reply

PrintingGains Sep. 11 at 12:22 PM

$TPST what price is the private placement at?

4 · Reply

Xamayca Sep. 11 at 12:22 PM

$TPST Bestvtime to get in deal will be announced by Oct 29

0 · Reply

Siesta94 Sep. 11 at 12:20 PM

$TPST Piece of shit - eternal dilution before bankruptcy…

1 · Reply

Michl2000 Sep. 11 at 12:15 PM

$TPST Brady and Angel are dirty bastards 🫵👊

1 · Reply

TwongStocks Sep. 11 at 12:12 PM

$TPST It looks like the warrants will require shareholder approval. They will not be exercisable until they are approved by shareholders. "The series C warrants and the series D warrants will have an exercise price of $0.805 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”)"

1 · Reply

TwongStocks Sep. 11 at 12:04 PM

$TPST Tempest Therapeutics Announces Up to $7.5 Million Private Placement https://ir.tempesttx.com/news-releases/news-release-details/tempest-therapeutics-announces-75-million-private-placement • $2.5M upfront from sales of 3,105,591 shares at $0.805. • 3,105,591 Series C warrants with a $0.805 exercise price. • 3,105,591 Series D warrants with a $0.805 exercise price. • Full $7.5M in gross proceeds if all warrants are exercised. For now, it is $2.5M upfront. • Private placement. Registration stetement will be filed at a later date

0 · Reply

Stock_Catcher Sep. 11 at 12:00 PM

$TPST Tempest Therapeutics Announces Up to $7.5 Million Private Placement

0 · Reply

josegodoy Sep. 11 at 7:33 AM

$TPST whatever happens (up OR down) don’t be surprise. Note: if I’m not mistaken she has breached a long term trend line (if not, she’s close)….if you read my previous posts you know why I mean. To be clear, NO ONE KNOWS WHERE SHE’S GOING!!!!

0 · Reply

Xamayca Sep. 10 at 9:18 PM

$TPST Added at .81

0 · Reply

Michl2000 Sep. 10 at 7:47 PM

$TPST not reality but manipulation and pretense count in this fantastic biotech world

0 · Reply

Market Cap	13.43M
Revenue (ttm)	0.00
Net Income (ttm)	-26.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	783,600
Avg Vol	237,766
Day's Range	N/A - N/A
Shares Out	16.54M
Stochastic %K	14%
Beta	-1.68
Analysts	Sell
Price Target	$11.00